Kelly McMasters is an Oncology physician affiliated with University of Louisville. OpenAlex indexes 633 publications with 36,623 citations (h-index 82); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Surgical Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
401 E Chestnut St
Suite 710
Louisville, KY 402025700
Telephone
502-583-8303Registry record last updated 30 Jul 2009.
Clinical trials
- Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
Sponsor: Kelly McMasters
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Integra LifeSciences CorporationProgram year20241 payment
- Integra LifeSciences CorporationProgram year20231 payment
- Merck Sharp & Dohme LLCProgram year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
52%Short-acting sulfonamides52%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsMetabolism & gastrointestinal
48%Antidiarrheal microorganisms48%Zenpep100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2002–2005 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Inducing trained immunity in pro-metastatic macrophages to control tumor metastasis
Nature Immunology
2023 - Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
New England Journal of Medicine
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Stephen McClave, MD
University of Louisville
Robert Friedland, MD
University of Louisville
Charles Scoggins, MD
University of Louisville
Hiram Polk, MD
University of Louisville
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”